Drugs / Bifidobacterium tetravaccae
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07306988 | Apr 2025 → Jun 2026 overdue | Helicobacter pylori infectious disease, metabolic syndrome X | Nanjing First Hospital, Nanjing Medical University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bifidobacterium tetravaccae | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07306988 ↗ |
| Route | Oral | “Patients receive oral vonoprazan 20 mg twice daily, amoxicillin 1000 mg three times daily, and Bifidobacterium tetravaccae probiotic tablets” NCT07306988 ↗ |